OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
January 02, 2014
With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.
December 19, 2013
ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.
Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.
CMC Biologics and OnoSynergy form an agreement from cell-line development.
Pfizer appoints management changes to take effect in 2014.
December 18, 2013
Operator training, preventive maintenance, and regularly scheduled calibration help prevent the manufacture of off-weight tablets.
Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.
December 12, 2013
BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.
Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).
December 06, 2013
Alvotech plans investment in biosimilars portfolio and manufacturing facility.